Could a drug combo free kidney transplant patients from lifelong pills?

NCT ID NCT04803058

Terminated Disease control Sponsor: ITB-Med LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This phase 2 study tests whether a drug called TCD601 (siplizumab), combined with donor bone marrow cells and mild chemotherapy, can train the immune system to accept a new kidney without needing lifelong anti-rejection drugs. The trial involves 18 adults receiving a kidney from a living donor. The main goal is to see if participants can safely stop all immunosuppression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Siplizumab (TCD601) combined with donor bone marrow cells and chemotherapy drugs (fludarabine and cyclophosphamide)
What this could lead to: If it works, this could allow kidney transplant recipients to stop taking lifelong anti-rejection medications, reducing side effects and improving quality of life.
What could go wrong: This is a small, early-phase trial with only 18 participants. The approach is complex and carries risks from the chemotherapy and potential rejection. Success is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANTATION

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Samsung Medical University

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.